ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
TiNT: A phase II study of trametinib in paediatric, adolescent and young adult patients with neurofibromatosis type 1 associated plexiform neurofibromas or progressive optic pathway gliomas
Protocol ID
TiNT
Disease (Sub Disease)
Solid tumours
Diagnosis Stage
Relapsed/ refractory
Location
NSW, VIC, WA, SA, NZ, TAS
Sponsor
Australian and New Zealand Children's Haematology Oncology Group
Trial Status
Open
Sites
The Children's Hospital at Westmead
Perth Children's Hospital
Monash Children's Hospital
Sydney Children's Hospital
John Hunter Children's Hospital
Royal Children's Hospital
Royal Hobart Hospital
Christchurch Hospital
Starship Hospital
Women's & Children's Hospital
Study Type
Treatment
Phase
Phase 2
Age Eligibility
3 Months to 25 Years
ANZCTR
ACTRN12620001229965
Back to Registry
Study Title TiNT: A phase II study of trametinib in paediatric adolescent and young adult patients with neurofibromatosis type 1 associated plexiform neurofibromas or progressive optic pathway gliomas
Protocol ID TiNT
Disease (Sub Disease) Solid tumours
Diagnosis Stage Relapsed/ refractory
Location NSW / VIC / WA / SA / NZ / TAS
Sponsor Australian and New Zealand Children's Haematology Oncology Group
Links https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379244&isReview=true
Trial Status Open
Trial Open Date 01/03/2021
Sites The Children's Hospital at Westmead / Perth Children's Hospital / Monash Children's Hospital/ Sydney Children's Hospital / John Hunter Children's Hospital/ Royal Children's Hospital / Royal Hobart Hospital/ Christchurch Hospital / Starship Hospital/ Women's & Children's Hospital
Study Type Treatment
Phase Phase 2
Age Eligibility 3 Months to 25 Years
ANZCTR ACTRN12620001229965

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168